Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The potential role of nicotine in tobacco dependence was investigated using the strategies of abuse liability assessment. Eight male volunteer cigarette smokers with histories of drug abuse resided on a research ward for the duration of the study. Each subject was tested with three doses of i.v. nicotine (0.75, 1.5 and 3.0 mg/10-sec infusion) and placebo each test day, and with three doses of inhaled nicotine, in the form of research cigarette smoke (0.4, 1.4 and 2.9 mg estimated yield) and placebo (sham-smoking), given on alternate test days. Each subject was tested on 4 days with both routes of administration, according to identical experimental protocols. Physiologic, subjective and observer data were collected at intervals ranging from 15 sec to 10 min beginning 10 min before drug administration and continuing for 30 min after administration. Both i.v. and inhaled nicotine produced dose-related increases in heart rate and blood pressure, and i.v. nicotine produced a transient bradycardia in four subjects during the first 30 sec after drug administration. Skin temperature was decreased by nicotine and pupil diameter was not consistently changed. Ratings of drug dose "strength" and drug "liking" were directly related to dose level whereas "desire to smoke cigarettes" was inversely related. Scores on the Morphine-Benzedrine Group (or Euphoria) scale of the Addiction Research Center Inventory were elevated by nicotine, and i.v. doses were identified frequently as cocaine. Signs and symptoms were similar for nicotine across the two routes of administration and included coughing, dizziness, nausea and relaxed feelings. Nicotine shared the pharmacologic profile of prototypic drugs of abuse. The study supports the hypothesis that the role of nicotine in tobacco dependence is equivalent to the role of other psychoactive drugs in substance abuse, e.g., to the role of cocaine in coca leaf use.
 ...
PMID:Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. 400 94

We discuss the case of a 24-year-old black woman at 33--34 weeks gestation, who after intravenous injection of Talwin presented with the following symptom complex: pyrexia, nausea, vomiting, shaking, chills, headache, myalgias, polyarthralgias, severe abdominal pain and "contractions." This symptomatology presents a complex diagnostic problem. Systematic laboratory evaluation eliminated more common etiologies, i.e., sub-acute bacterial endocarditis, HAA + hepatitis, placental abruption, chorioamnionitis, and urinary tract infection. The Talwin had been filtered through cotton ball. History plus exclusion of other etiologies led to the diagnosis of "cotton fever." The available literature is reviewed, and the importance of recognizing this entity when servicing a pregnant population with a high rate of drug abuse is discussed.
 ...
PMID:Cotton fever and pregnancy. A confusing clinical problem. 721 12

Abuse of intravenous crushed Talwin (pentazocine) and Ritalin (methylphenidate) tablets has not been fully described. The objective of this study was to characterize intravenous pentazocine/methylphenidate abuse in emergency department patients and compare its clinical toxicity to pentazocine/tripelennamine. Cases of intravenous pentazocine/methylphenidate abuse presenting to the Truman Medical Center Emergency Department between August 1987 and November 1992 were identified. Information regarding patient demographics, drug abuse, chief complaints, evaluation, treatment, and disposition were obtained from the emergency department record. The clinical presentation was compared to 104 published cases of pentazocine/tripelennamine abuse. Twenty nine patients were treated 34 times. They were 32 +/- 9 years of age, 48% male, and 52% black. Patients' chief complaints were cardiovascular/pulmonary (N = 8), central nervous system (N = 7), localized infection (N = 7), gastrointestinal (N = 5), malaise (N = 5), trauma (N = 1), and gynecologic (N = 1). Treatment was primarily supportive and included supplemental oxygen and intravenous fluids. The clinical findings were similar to those reported for pentazocine/tripelennamine; 58% had the typical symptom complex of chest pain, anxiety, muscle spasm, dizziness, and nausea.
 ...
PMID:IV pentazocine/methylphenidate abuse--the clinical toxicity of another Ts and blues combination. 793 13

Over a 3-year period, 15 patients with severe hyponatremia were referred to our emergency room from a nearby psychiatric institution. This article reports on 36 episodes of symptomatic hyponatremia in those 15 patients. All but two of the patients were receiving antipsychotic medications; one patient was taking a nonsteroidal anti-inflammatory drug, and one patient was taking an oral hypoglycemic agent. Thirteen patients were chronic schizophrenics, one had a bipolar depressive disorder with psychotic features, and one patient had no psychiatric disorder. Patients presented with seizures, change in mental status, and vegetative symptoms (nausea, vomiting, and diarrhea) associated with hyponatremia and water intoxication. Exacerbation of the patients' underlying illness, psychogenic polydipsia, compulsive smoking, alcoholic cirrhosis, drug abuse, and neuroleptic and other medications are thought to be the major causes of acute hyponatremia in these patients.
 ...
PMID:Symptomatic hyponatremia associated with psychosis, medications, and smoking. 809 75

A survey of 72 patients at an AIDS clinic regarding self-medication with recreational drugs for medical or psychological conditions related to their illness disclosed that marijuana was the primary drug used. The perceived benefit was for gastrointestinal conditions such as nausea, vomiting, indigestion and appetite improvement. Use of other "recreational" drugs as self-medication was reported to usually be ineffective or to worsen the condition they sought to help. Fifty-eight percent of patients reported some attempt to self-medicate. Thirty-two percent were currently using marijuana, and most admitted to pre-AIDS marijuana use. Fifty-seven percent of the sample reported some pre-AIDS drug use, primarily alcohol and marijuana. Results are discussed in terms of potential clinical problems arising from continued recreational drug use among AIDS patients.
 ...
PMID:Medical use of recreational drugs by AIDS patients. 924 37

Widespread use of smoked marijuana in the San Francisco Bay Area as a treatment for HIV-related anorexia and weight loss, as well as nausea related to prescribed therapy, prompted the design of a clinical trial to evaluate the safety and effectiveness of this controlled substance. The Community Consortium--the Bay Area's community-based HIV clinical trials organization--designed a first pilot evaluation of smoked marijuana compared to oral tetrahydrocannabinol (THC, synthesized as dronabinol or Marinol) in 1993. A legal source of marijuana could not be identified. Two subsequent applications to the National Institutes of Health were submitted in 1996 and 1997. During the intervening period, increasing numbers of people with HIV infection were obtaining marijuana for "medicinal use" from local Cannabis Buyer's Clubs. In November 1996, California voters endorsed the medical use of marijuana by approving Proposition 215. The federal government's attempt to oppose the voters' mandate led to public outrage. Organized medicine demanded more studies into marijuana's potential use as medicine. The consortium's 1997 proposal to evaluate the potential interaction between THC and widely-prescribed protease inhibitors was positively received. Funding and study-required marijuana cigarettes have been obtained from the National Institute of Drug Abuse, and the first subjects are being enrolled in the trial. When politically sensitive research proposals include sound science, they can prevail if investigators are willing to persist.
 ...
PMID:Medical marijuana: tribulations and trials. 969 78

Although controversial, opioid analgesics have been prescribed for patients with chronic facial pain. Based primarily on survey data and a few well-controlled clinical trials, long-term opioid treatment provides adequate pain reduction in 41% to 100% of patients with chronic nonmalignant pain. However, only 25% of chronic facial pain patients reported adequate pain relief with chronic opioid treatment. Work, home, and school function are generally reestablished or maintained during chronic opioid treatment, but 25% to 38% of patients remain dysfunctional, and one study indicated that 20% of patients became dysfunctional during treatment. Chronic opioid treatment is associated with many transient side effects; constipation, dizziness, nausea, vomiting, itching, and fatigue have been reported in 5% to 42% of patients taking opioids over 1 year. Although survey studies suggest that the risks of addiction are low in typical patients, drug abuse rates up to 17.3% and prescription abuse rates up to 27.6% were reported within groups of chronic opioid users. Chronic opioid use induces analgesic tolerance and physical dependence, which may result in a serious abstinence syndrome in users and children born to users. Chronic opioid use also may induce harmful immune system changes, diminish cognitive and motor function, and produce nociceptive hyperexcitability. This article shows that the use of long-term opioids for chronic facial pain is not justified based on the available data. Despite these perceived problems, there is anecdotal evidence that chronic facial pain patients will respond positively to opioid analgesics. In our experience, the pain assessment scale and a modification of the World Health Organization's three-step analgesic ladder, which prescribes nonopioid analgesics, can be the starting point for the successful management of chronic facial pain.
 ...
PMID:The use of nonopioid drugs in management of chronic orofacial pain. 973 70

A 40-year-old HIV-infected woman developed nausea, vomiting, and epigastric pain and died following her third dose (per study protocol) of interleukin (IL)-2. Her HIV infection was diagnosed in 1996. Her last CD4 cell count was 390/microL, and her viral load was negligible (as of November 28, 1998). She had no known general risk factors for thrombosis other than HIV infection, injection drug abuse, and antiretroviral therapy with indinavir. Abdominal films showed no sign of mechanical obstruction but a generalized gas distention of the bowel, which was suggestive of paralytic ileus. Autopsy revealed dilation of the small bowel with extensive necrosis and hemorrhage involving all the segments. The superior and inferior mesenteric arteries revealed severe atherosclerosis. The stenotic celiac artery was occluded by a recent thrombus at the aortic ostium. Clinicians need to be aware of the potential for thrombosis and accelerated atherosclerosis in HIV-infected patients. Both injection drug abuse and protease inhibitors, such as indinavir, have been shown to be risk factors for thrombosis. However, it is likely IL-2 contributed to the severe thrombosis in this patient, although definitive proof is lacking. An acute awareness of intestinal infarction in HIV-infected patients is warranted.
 ...
PMID:Case report. Intestinal infarction due to vascular catastrophe in an HIV-infected patient. 1118 43

The Clinton Administration is continuing to block the research efforts of Dr. Donald Abrams, University of California, San Francisco, to study the safety and effectiveness of marijuana in stimulating the appetites and reducing nausea of people with AIDS wasting syndrome. Dr. Abrams does not require money for the study, but he does need a supply of the marijuana. Since the National Institute on Drug Abuse (NIDA) is the Federal agency responsible for the supply of marijuana for clinical research, NIDA informed Dr. Abrams that he must submit a grant application to an NIH peer-review panel that will determine whether the research protocol has scientific merit. After submitting a grant proposal, the National Institute of Allergy and Infectious Diseases (NIAID) rejected Dr. Abrams' application. The Marijuana Policy Project contends that the peer-review approval is a ploy to block research, or delay it until after the presidential election. They continue to work to persuade Congress to require NIDA to provide marijuana to all FDA-approved medicinal marijuana studies, as it did in the late 1970s and early 1980s. A sample letter-to-the-editor advocating the use of marijuana as a useful medicine for the treatment of AIDS and other diseases is also included.
 ...
PMID:Medical marijuana--once again--blocked. Marijuana Policy Project. 1136 29

A 21-year-old woman experienced severe headache and nausea one hour after taking pills containing 160 mg of phenylpropanolamine for common cold. She had no previous history of drug abuse or hypertension. Physical examination revealed slight left-sided hemiparesis. Her blood pressure was 100/52 mmHg. Subcortical hemorrhage was noted in the right frontal lobe with a cranial computed tomography. On the seventh hospital day, cerebral angiography demonstrated with segmental narrowing of a branch of the right anterior cerebral artery, indicating the presence of focal angitis. This finding disappeared on the 35th hospital day. In the majority of the reported cases of the intracerebal hemorrhage associated with the ingestion of phenylpropanolamine, focal angitis rather than induced hypertension is considered to be a causative factor for hemorrhage. Thus, we would like to emphasize that the administration of phenylpropanolamine should be avoided, even to the patients without hypertention or past history of intracerebral hemorrhage.
 ...
PMID:[A case with cerebral subcortical hemorrhage following the administration of phenylpropanolamine]. 1180 51


1 2 3 Next >>